Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 198

1.

TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer.

Fu Z, Jiao Y, Li Y, Ji B, Jia B, Liu B.

Medicine (Baltimore). 2019 Dec;98(51):e18487. doi: 10.1097/MD.0000000000018487.

2.

Aspirin use and pancreatic cancer risk: A systematic review of observational studies.

Sun J, Li Y, Liu L, Jiang Z, Liu G.

Medicine (Baltimore). 2019 Dec;98(51):e18033. doi: 10.1097/MD.0000000000018033.

3.

Emerging incidence trends and application of curative treatments of pancreatic cancer in the USA.

Pei X, Song F, Wang Z.

Medicine (Baltimore). 2019 Dec;98(51):e17175. doi: 10.1097/MD.0000000000017175.

4.

Intracellular Ion Channels in Pancreas Cancer.

Patel SH, Edwards MJ, Ahmad SA.

Cell Physiol Biochem. 2019;53(S1):44-51. doi: 10.33594/000000193. Review.

5.

Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013.

Tramontano AC, Chen Y, Watson TR, Eckel A, Sheehan DF, Peters MLB, Pandharipande PV, Hur C, Kong CY.

Medicine (Baltimore). 2019 Dec;98(49):e18082. doi: 10.1097/MD.0000000000018082.

6.

Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.

Fazio N, Cella CA, Del Re M, Laffi A, Rubino M, Zagami P, Spada F.

Expert Opin Drug Metab Toxicol. 2019 Dec;15(12):993-1004. doi: 10.1080/17425255.2019.1700951. Epub 2019 Dec 12. Review.

PMID:
31794273
7.

C-reactive protein/albumin ratio is a prognostic indicator in Asians with pancreatic cancers: A meta-analysis.

Fu YJ, Li KZ, Bai JH, Liang ZQ.

Medicine (Baltimore). 2019 Nov;98(48):e18219. doi: 10.1097/MD.0000000000018219.

8.

Diffusion-weighted image improves detectability of magnetic resonance cholangiopancreatography for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm.

Kawakami S, Fukasawa M, Shimizu T, Ichikawa S, Sato T, Takano S, Kadokura M, Shindo H, Takahashi E, Hirose S, Fukasawa Y, Hayakawa H, Nakayama Y, Yamaguchi T, Inoue T, Maekawa S, Kawaida H, Motosugi U, Onishi H, Enomoto N.

Medicine (Baltimore). 2019 Nov;98(47):e18039. doi: 10.1097/MD.0000000000018039.

9.

Study on the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine: A study protocol of a multicenter prospective cohort study.

Jiang J, Liu R, Zhang Z, Zhang X, Qi R, Chen S, Zhang X, Xi Y, Guo Q, Zheng H, Hua B.

Medicine (Baltimore). 2019 Nov;98(47):e17975. doi: 10.1097/MD.0000000000017975.

10.

New therapeutic targets in pancreatic cancer.

Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M.

Cancer Treat Rev. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11. Review.

PMID:
31739115
11.

New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism.

Capula M, Mantini G, Funel N, Giovannetti E.

Expert Rev Clin Pharmacol. 2019 Dec;12(12):1081-1090. doi: 10.1080/17512433.2019.1693256. Epub 2019 Nov 24. Review.

PMID:
31721608
12.

Influence of non-jaundice stage at diagnosis on clinicopathological features and long-term survival of patients with periampullary carcinomas.

Peng X, Jiao X, Zhao P, Zhu R, Sun Y, Zhou L.

Medicine (Baltimore). 2019 Nov;98(45):e17673. doi: 10.1097/MD.0000000000017673.

13.

The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis.

Wang S, Zhang J, Liu S, Zhang J.

Medicine (Baltimore). 2019 Nov;98(44):e17773. doi: 10.1097/MD.0000000000017773.

14.

Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium.

Gut. 2020 Jan;69(1):7-17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31.

PMID:
31672839
15.

Pancreatic Neuroendocrine Tumors - Case Series and Literature Review.

Mihalache O, Doran H, Poiană C, Bîrligea A, Cîrstea MO, Pătraşcu T.

Chirurgia (Bucur). 2019 Sept-Oct;114(5):630-638. doi: 10.21614/chirurgia.114.5.630. Review.

16.

Pancreatic Cancer.

Moore A, Donahue T.

JAMA. 2019 Oct 8;322(14):1426. doi: 10.1001/jama.2019.14699. No abstract available.

PMID:
31593274
17.

Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis.

Forster T, Huettner FJ, Springfeld C, Loehr M, Kalkum E, Hackbusch M, Hackert T, Diener MK, Probst P.

Oncology. 2020;98(1):53-60. doi: 10.1159/000502844. Epub 2019 Oct 2.

18.

Mechanisms Underlying Metastatic Pancreatic Cancer.

Pitarresi JR, Rustgi AK.

Adv Exp Med Biol. 2019;1164:3-10. doi: 10.1007/978-3-030-22254-3_1. Review.

PMID:
31576536
19.

A Teacher for All Seasons.

Khine A.

JAMA. 2019 Sep 24;322(12):1145-1146. doi: 10.1001/jama.2019.14741. No abstract available.

PMID:
31550035
20.

Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.

Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N.

Cancer Treat Rev. 2019 Nov;80:101895. doi: 10.1016/j.ctrv.2019.101895. Epub 2019 Sep 6.

PMID:
31542591

Supplemental Content

Loading ...
Support Center